National Health Investors Form 4 Filings

NATIONAL HEALTH INVESTORS INC director Robert A. McCabe Jr. reported an open-market purchase of 890 shares of common stock at $71.6485 per share. Following this transaction, he directly owns 44,158.96 shares. This filing reflects a modest increase in his personal investment in the company.

NATIONAL HEALTH INVESTORS INC director James R. Jobe reported a bona fide gift of 225 shares of Common Stock on June 5, 2026, transferred at a price of $0.00 per share. After this gift, he directly holds 33,272 Common Stock shares according to the filing.

National Health Investors CEO and President D. Eric Mendelsohn bought 1,500 shares of common stock in an open-market purchase at $68.84 per share. After this transaction, he directly owns 133,316 shares, indicating a small increase in his personal stake in the company.

NATIONAL HEALTH INVESTORS INC CFO and EVP Finance John L. Spaid reported a small tax-related share disposition. On May 5, 2026, 314 shares of common stock were withheld by the company at $73.09 per share to cover tax obligations tied to vesting restricted stock. After this withholding, he directly holds about 56,286.6372 shares.

National Health Investors CEO and President D. Eric Mendelsohn reported a routine tax-withholding transaction related to equity compensation. On May 5, 2026, 394 shares of Common Stock were withheld by the company at $73.09 per share to cover tax obligations on vesting restricted stock. After this non-market disposition, he directly holds 131,816 shares of National Health Investors common stock.

NATIONAL HEALTH INVESTORS INC senior vice president and chief accounting officer David L. Travis reported a routine tax-related share disposition. On May 5, 2026, the issuer withheld 282 shares of common stock at $73.09 per share to cover tax obligations from vesting restricted stock. After this withholding, Travis directly held 40,565 common shares, indicating the transaction affected only a small portion of his overall position and did not involve an open-market sale.

PASCOE KEVIN CARLTON reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors Inc. reported that Chief Investment Officer Kevin Carlton Pascoe received a grant of 4,726 shares of common stock on March 3, 2026, at no cash cost to him. After this compensation-related award, he directly holds 73,082 common shares.

The filing is an amended Form 4 that corrects an earlier administrative error, which had overstated the number of shares awarded on that date by 346 shares. This amendment updates the record to show the accurate number of shares granted.

Spaid John L reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors Inc. reported that CFO and EVP Finance John L. Spaid received a corrected equity award of 5,072 shares of Common Stock on March 3, 2026, recorded at $0.00 per share as a compensation grant. An earlier report understated this award by 346 shares, and this amended Form 4 updates the figure. Following the grant, Spaid directly owns 56,600.637 shares of National Health Investors common stock.

Donohue Lilly reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors director Lilly Donohue reported receiving a grant of 1,268 shares of common stock as restricted stock.

The award was granted on March 3, 2026 and will vest in full on March 3, 2027, as long as she continues serving as a director through that date. Following this grant, her directly owned stake is 1,268 shares.

COLDEN TRACY M J reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors director receives stock grant. Director Tracy M. J. Colden was awarded 1,268 shares of National Health Investors common stock on March 3, 2026 as restricted stock. These shares vest in full on March 3, 2027, subject to continued board service, bringing her direct holdings to 12,858 shares.

Todd Candice W reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors Inc. director Candice W. Todd received a grant of 1,268 shares of common stock on March 3, 2026. This restricted stock award vests in full on March 3, 2027, if she continues serving as a director through that date, bringing her direct holdings to 2,563 shares.

National Health Investors director Robert Chapin reported an equity award of common stock. He acquired 1,268 shares of restricted stock on March 3, 2026 at no purchase price as a grant for board service. The award vests in full on March 3, 2027, provided he continues serving as a director through that date.

Jobe James R reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors director James R. Jobe received a grant of 1,268 shares of common stock on March 3, 2026 at no cost, increasing his directly held shares to 1,268.

The restricted stock vests in full on March 3, 2027, contingent on his continued board service. Additional holdings include 33,497 common shares jointly held with his spouse and 500 common shares in an IRA SEP as of that date.

National Health Investors director receives stock grant

NATIONAL HEALTH INVESTORS INC reported that director Robert A. McCabe Jr. acquired 1,268 shares of common stock as a restricted stock award on March 3, 2026. The grant was made at no cash cost and increases his direct holdings to 43,268.96 shares.

The restricted stock vests in full on March 3, 2027, provided he continues serving as a director through that date. Until vesting, these shares typically remain subject to forfeiture conditions tied to his board service.

National Health Investors Inc CFO and EVP Finance John L. Spaid reported several equity transactions on March 3, 2026. He exercised stock options for 15,000 shares of common stock at $73.34 per share and received a grant of 4,726 restricted shares that vest in three equal annual installments beginning on March 3, 2027, subject to continued service. To cover tax obligations related to vesting restricted stock, 13,594 shares and an additional 511 shares were disposed of through issuer share withholding at a price of $86.75 per share. After these transactions, he directly held 56,254.6372 shares of common stock.

PASCOE KEVIN CARLTON reported acquisition or exercise transactions in this Form 4 filing.

NATIONAL HEALTH INVESTORS INC reported an insider equity award for Chief Investment Officer Kevin Carlton Pascoe. On March 3, 2026 he received a grant of 5,072 shares of common stock as restricted stock, recorded at a per-share price of $0.0000.

According to the filing, this restricted stock grant vests in three equal annual installments on each anniversary of the grant date beginning March 3, 2027, subject to his continued service through each vesting date. After this award, he directly held 73,428 shares of common stock.

NATIONAL HEALTH INVESTORS INC CEO and President D. Eric Mendelsohn received a grant of 14,409 shares of common stock on March 3, 2026 at a price of $0.0000 per share. This restricted stock vests in three equal annual installments on each anniversary of the grant date beginning March 3, 2027, conditioned on continued service.

On the same date, 597 shares of common stock were disposed of at $86.75 per share to satisfy tax withholding obligations tied to restricted stock vesting on March 3, 2026. After these transactions, Mendelsohn directly held 132,210 common shares and 25,000 stock options.

National Health Investors Inc. reported that SVP and Chief Accounting Officer David L. Travis received a grant of 3,458 shares of common stock as restricted stock on March 3, 2026. According to the filing, this restricted stock vests in three equal annual installments on each anniversary of the grant date beginning March 3, 2027, subject to his continued service through each vesting date.

The company also withheld 411 shares of common stock at a price of $86.75 per share to cover tax withholding obligations related to restricted stock vesting on March 3, 2026. After these transactions, Travis directly owned 40,847 shares of common stock.

National Health Investors Inc reported that SVP, Legal Affairs Elizabeth Jackson Blankenship acquired 2,420 shares of common stock through a restricted stock grant at a stated price of $0.00 per share.

The restricted shares vest in three equal annual installments on each anniversary of the March 3, 2026 grant date, beginning March 3, 2027, subject to her continued service through each vesting date.

National Health Investors Inc. SVP and Chief Accounting Officer David L. Travis reported multiple equity transactions on February 23, 2026. He exercised stock options for a total of 25,000 shares of common stock at a stated price of $57.76 per share. In a separate transaction coded “F,” 19,322 shares of common stock at $90.03 per share were disposed of to satisfy tax-withholding obligations related to the option exercises. After these transactions, he directly owned 37,800 shares of National Health Investors common stock.

National Health Investors Chief Investment Officer Kevin Carlton Pascoe exercised stock options for 8,500 shares of common stock at a price of $57.76 per share on February 23, 2026.

To cover the exercise price or related tax obligations, 6,409 shares of common stock were disposed of through a tax-withholding transaction, leaving him with 68,356 shares of common stock held directly.

National Health Investors CEO and President D. Eric Mendelsohn reported option exercises and related tax share dispositions. On February 23, 2026, he exercised 13,334 stock options, receiving 13,334 shares of common stock at an exercise price of $57.76 per share.

To cover tax obligations associated with these equity awards, 10,192 shares and an additional 194 restricted shares were automatically withheld and disposed of at $90.03 per share. After these transactions, he directly owned 118,398 shares of National Health Investors common stock.

National Health Investors CFO John L. Spaid exercised stock options for 8,500 shares of common stock on February 23, 2026. The options converted into common shares at a reported price of $57.7600 per share.

To cover taxes related to these equity events, Spaid disposed of 6,312 shares of common stock and an additional 236 restricted shares at a reported price of $90.0300 per share, described as tax-withholding dispositions. Following these transactions, he directly owned 50,633.6372 shares of National Health Investors common stock.

NATIONAL HEALTH INVESTORS INC director COLDEN TRACY M J reported exercising stock options for 10,000 shares of common stock on February 19, 2026. The options converted into common shares at a reported price of $73.34 per share. To cover taxes and related obligations, 8,267 shares were disposed of through a tax-withholding transaction at $88.72 per share. After these transactions, the director directly owned 11,590 shares of NHI common stock.

NATIONAL HEALTH INVESTORS CEO and President D. Eric Mendelsohn exercised a stock option for 25,000 Stock Option (Right to Buy) 2025 and received 25,000 shares of Common Stock at $73.34 per share. To cover tax obligations, 22,055 Common shares were disposed of through a tax-withholding transaction at $91.02 per share, leaving 115,450 Common shares held directly after these transactions.

NATIONAL HEALTH INVESTORS INC director James R. Jobe exercised stock options for 10,000 shares of common stock on February 17, 2026. The options, labeled “Stock Option (Right to Buy) 2025,” covered 10,000 shares at a reported exercise price of $0.0000 per option.

The exercise resulted in 10,000 shares of Common Stock - Jointly held with spouse at $73.34 per share, increasing this joint holding to 41,555 shares. To cover the exercise price or tax obligations, 8,058 jointly held shares were disposed of at $91.02 per share under a tax-withholding transaction, reducing the joint position to 33,497 shares. A separate Common Stock - IRA SEP account is reported with 500 shares following the transactions.

National Health Investors director exercises options and settles taxes in shares. Director Robert A. McCabe Jr. exercised stock options for 10,000 shares of common stock at an exercise price of $73.34 per share on February 12, 2026. To cover exercise price or tax obligations, 8,180 shares of common stock were disposed of in a tax-withholding transaction at $89.66 per share. After these transactions, he directly beneficially owned 42,000.96 shares of National Health Investors common stock, including 1,742.79 shares previously acquired in 2025 through a dividend reinvestment plan.

PASCOE KEVIN CARLTON reported multiple insider transaction types in a Form 4 filing for NHI. The filing lists transactions totaling 43,463 shares at a weighted average price of $80.39 per share. Following the reported transactions, holdings were 66,265 shares.

National Health Investors (NHI) senior vice president and chief accounting officer Travis David L exercised multiple stock options on February 9, 2026, acquiring common shares through option exercises at exercise prices of $53.41 and $54.73 per share.

Following these exercises, a separate transaction used 28,868 common shares at $85.10 in a tax-withholding disposition, leaving him with 32,122 shares of NHI common stock held directly after all reported transactions.

National Health Investors director Candice W. Todd reported an option exercise and related share transactions. On 02/05/2026, she exercised 10,000 shares under a 2025 stock option at $73.34 per share, receiving 10,000 common shares. On the same date, 8,705 common shares were disposed of at $84.26 per share, leaving 1,295 common shares held directly.

National Health Investors Inc.'s Chief Investment Officer, Kevin C. Pascoe, reported multiple equity transactions in the company’s common stock. On January 30, 2026, he exercised two stock option awards for 8,500 shares each at exercise prices of $54.73 and $57.76, increasing his directly held common shares to 78,330.

On the same date, he reported a disposition coded "F" of 13,602 common shares at $82.12 per share. After these transactions, Pascoe directly beneficially owned 64,728 shares of National Health Investors common stock.

National Health Investors senior vice president and Chief Transaction Officer Kristin Sallee Gaines reported several equity transactions in company stock. On February 1, 2026, she exercised three tranches of 2022 stock options for 18,333, 18,333, and 18,334 shares at an exercise price of $53.41 per share.

The option exercises delivered the same numbers of Common Stock shares, increasing her direct holdings up to 116,944 shares. On the same date, she disposed of 43,181 common shares at $82.12 per share, resulting in a remaining directly owned balance of 73,763 shares.

National Health Investors director Robert G. Adams reported option exercises and related share transactions dated January 27, 2026. He exercised 25,000 stock options granted February 25, 2021 at $69.20 per share and 10,000 stock options granted in 2025 at $73.34 per share, receiving common stock held indirectly as Trustee. To cover taxes, 31,093 shares of common stock were disposed of at $79.23 per share under transaction code F, also reported as indirectly owned as Trustee. Following these transactions, 184,455 common shares are reported as indirectly owned as Trustee, 40,000 shares are indirectly owned as Trustee – CLAT, and 342,096 shares are indirectly owned through a Family Partnership.

National Health Investors, Inc. (NHI) CFO and EVP Finance John L. Spaid reported multiple equity transactions dated January 16, 2026. He exercised three stock option grants for common stock: 8,500 shares at $54.73, 8,500 shares at $57.76, and 15,000 shares at $73.34, all coded "M" for option exercises. Corresponding non-derivative entries show the same share amounts of common stock acquired at those prices. The filing also reports a disposition of 27,742 common shares at $80.43, coded "F" and treated as a sale-type transaction. After these moves, Spaid directly beneficially owns 48,681.6372 shares of NHI common stock.

National Health Investors CEO and President Eric D. Mendelsohn, who is also a director, reported multiple equity transactions dated January 15, 2026. He exercised several tranches of stock options, acquiring common stock in amounts of 41,666, 41,666, 41,668, 13,334 and 13,333 shares at exercise prices of $69.2, $69.2, $69.2, $54.73 and $57.76 per share, respectively, all held directly.

The filing also lists a separate transaction coded "F" for 135,295 shares of common stock at $79.23 per share, after which Mendelsohn directly owned 112,505 shares of National Health Investors common stock.

National Health Investors director reports option exercise and share sale. Director Robert A. McCabe Jr. exercised 25,000 stock options granted in 2021 at an exercise price of $69.20 per share, receiving the same number of common shares. On the same day, 21,836 common shares were disposed of at $79.23 per share in a transaction coded “F,” indicating shares withheld or sold to cover taxes. After these transactions, he directly owned 38,438.17 shares of common stock and held 10,000 additional stock options with a $73.34 exercise price that become exercisable on March 3, 2025 and expire on March 3, 2030.

National Health Investors Inc. director reports multiple stock option exercises and share withholding on December 9, 2025. The reporting person, acting as trustee, exercised several stock options, acquiring 25,000 shares of common stock at an exercise price of $69.2, another 25,000 shares at $53.41, and three additional blocks of 10,000 shares each at exercise prices of $54.73, $57.76, and $73.34. All of these were coded as option exercises. The filing also shows a transaction coded "F" in which 62,827 shares of common stock were disposed of at $78.37, leaving 127,358 shares of common stock beneficially owned indirectly as trustee after the reported transactions.

National Health Investors, Inc. (NHI) reported insider activity by a director who jointly holds shares with a spouse. On 11/20/2025, the director exercised a stock option to acquire 25,000 shares of common stock at an exercise price of $69.20 per share. On the same date, 22,135 shares of jointly held common stock were disposed of in a transaction coded "F," indicating shares were surrendered, typically to cover tax obligations, at a price of $78.16 per share. After these transactions, the director beneficially owned 31,555 shares of common stock jointly with a spouse and 500 shares in an IRA SEP, along with 10,000 stock options exercisable beginning 03/03/2025.

National Health Investors (NHI) insider filings show option exercises and open-market transactions by Travis David L. The filing reports two acquisitions of 11,666 and 11,334 shares of common stock on 09/23/2025 at a reported price of $69.20 each, and a disposition of 20,765 shares on 09/23/2025 at $80.06 per share. Following the reported non-derivative transactions, the filing lists beneficial ownership totals of 33,221, 44,555, and 23,790 shares in the respective reported lines. The Form 4 also discloses detailed option holdings and exercisable schedules, including multiple tranches with exercise prices ranging from $53.41 to $73.34 and expiration dates through 2030, and shows that several option exercises on 09/23/2025 resulted in zero remaining derivative securities for those specific grants. The report is signed by the reporting person on 09/24/2025.